Synthetic Biologics Revenue, Growth & Competitor Profile

DBA THERIVA BIOLOGICS, INC.

Company Profile & Annual Report for Synthetic Biologics

Access the complete profile.

Synthetic Biologics Fast Facts

Revenue	$1 - $10 million    See Exact Annual Revenue
Employees	10 - 100Exact Company Size
Primary Industry	5411 Legal Services
Additional NAICS Codes	541711 Research & Development in Biotechnology
Address	9605 Medical Center Dr Ste 270 Rockville, MD 20850

Note: Revenues for privately held companies are statistical evaluations.


Synthetic Biologics's Annual Report & Profile shows critical firmographic facts:

• What is the company's size? (Annual sales and employees)
  • Synthetic Biologics's annual revenues are $1 - $10 million (see exact revenue data)
• What industry is the company in?
  • Synthetic Biologics is classified as operating in the Legal Services industry, NAICS Code 5411.

Synthetic Biologics Annual Revenue and Growth Rate

Synthetic Biologics	Revenue Est. ($ Million)	Growth Rate (%)	# Employees
2025	$1 - $10 million Details in Premium Report
2024
2023
2021
2020
2019

1-Year Growth Rate: 3-Year Growth Rate (CAGR):

Note: Synthetic Biologics's revenues are gauged from an analysis of company filings.

Synthetic Biologics's Income Statement (based on Industry Averages)

Synthetic Biologics P&L	$ Millions
Revenue (Sales)
Cost of Goods Sold
Gross Profit
Operating Expenses
Advertising
Salaries and wages
Other Operating Expenses
Total Operating Expenses
Operating Income
EBITDA
EBIT (Earnings Before Interest and Taxes)
Net Profit

Trademark Applications

Trademark applications show the products and services that Synthetic Biologics is developing and marketing. Synthetic Biologics doesn't have any recent trademark applications, indicating Synthetic Biologics is focusing on its existing business rather than expanding into new products and markets. Trademarks may include brand names, product names, logos and slogans.

Trademark	Date
THERIVA Pharmaceutical preparations for the treatment, prevention and alleviation of gastrointestinal diseases, infections, dysbiosis, and disorders; pharmaceutical preparations for the treatment of metabolic diseases and disorders; Pharmaceuticals, namely, pharmaceutical preparations for gastrointestinal health, gastrointestinal dysbiosis and systemic illnesses associated with gastrointestinal dysbiosis, gastrointestinal disorders and systemic illnesses associated with gastrointestinal disorders, gastrointestinal diseases and systemic illnesses associated with gastrointestinal diseases, gastrointestinal infections and systemic illnesses associated with gastrointestinal infections, used to maintain health and restore health to a human or animal subject via treatment of a disturbed microbial community and prevention of microbial community disruption; Pharmaceutical preparations, namely, preparations for use in the treatment of cancer and tumors; oncolytic viral therapies; biological therapies for use in the treatment of cancer and tumors	02/02/2022
TRILLEON PHARMACEUTICALS Pharmaceutical preparations for the treatment, prevention and alleviation of gastrointestinal diseases, infections, dysbiosis, and disorders; pharmaceutical preparations for the treatment of metabolic diseases and disorders; Pharmaceuticals, namely, pharmaceutical preparations for gastrointestinal health, gastrointestinal dysbiosis and systemic illnesses associated with gastrointestinal dysbiosis, gastrointestinal disorders and systemic illnesses associated with gastrointestinal disorders, gastrointestinal diseases and systemic illnesses associated with gastrointestinal diseases, gastrointestinal infections and systemic illnesses associated with gastrointestinal infections, used to maintain health and restore health to a human or animal subject via treatment of a disturbed microbial community and prevention of microbial community disruption	02/27/2017
ASYMPRI Pharmaceutical preparations for the treatment of gastrointestinal disease and disorders; pharmaceutical preparations for the treatment of metabolic disease and disorders	02/16/2016

See all trademarks and details in the Full Report.

Market Share of Synthetic Biologics's Largest Competitors

A competitive analysis shows these companies are in the same general field as Synthetic Biologics, even though they may not compete head-to-head. These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines. The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies. Competitive advantage comes from offering better pricing or superior products/service.

Company	Headquarters	Revenue ($ MM)
AUSTIN 316 FIDUCIARY LIMITED	Oceanside, NY	100
CONSILIO	Washington, DC	66
LATHAM & WATKINS	Los Angeles, CA	54
KIRKLAND & ELLIS	Chicago, IL	49
CO STATE FRATERNAL ORDER OF POLICE	Westminster, CO	44
GREENBERG TRAURIG P.A.	Miami, FL	42
PROFESSIONAL LAW ENFORCEMENT A	Rochester, MI	38
CHG COMPANIES	Midvale, UT	35
BAKER & MCKENZIE	Chicago, IL	33

Nearby Competitors

These companies are similar in business line and location to Synthetic Biologics. While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.

Company	Headquarters	Revenue ($ MM)
OFFIT KURMAN P.A.	Bethesda, MD	100
BWW LAW GROUP	Rockville, MD	37
SHULMAN ROGERS GANDAL PORDY & ECKER P.A.	Potomac, MD	33
FNC TITLE SERVICES	Rockville, MD	26
STEIN SPERLING BENNETT DE JONG DRIS OLL PC	Rockville, MD	20
AUTOMATED PRECISION	Rockville, MD	19

Future Competition: Synthetic Biologics's Fastest Growing Competitors

These companies are in the same general field as Synthetic Biologics and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.

Company	Revenue ($ MM)